Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Dr Marit Westerterp obtained her MSc degree in Bio-Pharmaceutical Sciences (2003), and PhD degree on Hyperlipidemia, Inflammation, and Atherosclerosis (2007) from Leiden University, The Netherlands. She performed postdoctoral research at Columbia University in the laboratory of Professor Alan Tall. She there identified that cholesterol efflux pathways have several anti-inflammatory effects, leading to suppression of stem cell mobilization, leukocytosis, atherogenesis, and auto-immunity. Dr Westerterp has received several awards, including the Roger Davis Award for Transitional Faculty in Lipoprotein Metabolism (2015), and the Daniel Steinberg and Irvine Page Awards from the ATVB Council of the American Heart Association (2017). She serves on the Editorial Boards of Circulation Research, and Arteriosclerosis, Thrombosis, and Vascular Biology. Supported by a VIDI grant from The Netherlands Organization of Scientific Research and a Rosalind Franklin Fellowship from the University Medical Center Groningen (UMCG), Dr Westerterp currently leads a research group as Associate Professor at the UMCG, University of Groningen, The Netherlands. Her research focuses on cholesterol transport and inflammation in atherogenesis.
Bart van de Sluis
Dr Bart van de Sluis graduated in Biology from the Utrecht University, the Netherlands. In 1998, he was appointed as a PhD student at the Department of Human Genetics at the Utrecht University, the Netherlands, under the supervision of Prof. Cisca Wijmenga. He received his PhD degree (cum laude, highest distinction in the Netherlands) in 2002 on the basis of the identification of a copper toxicosis gene (COMMD1, previous known as MURR1) in Bedlington terriers. As a post-doctoral fellow, he continued his scientific career in the lab of Dr Paul Liu at the Genetics and Molecular Biology Branch at the National Human Genome Research Institute (NIH, Bethesda, USA). He worked on a project to identify novel players in leukemogenesis and hematopoiesis. Mid-2004, he returned back to Utrecht as a post-doc on a joined project of Dr L. Klomp and Prof. C. Wijmenga. He characterized a Commd1 knockout mouse, which he generated in the lab of Dr Paul Liu at NIH. In March 2008, Dr van de Sluis moved to Groningen to set up his own research group to better understand how the trafficking of receptors (including members of the LDLR family) in the cell is regulated, and how inflammation is kept under control, with the focus on the NF-κB signaling pathway. He is using cellular and mouse models to study these different processes in great detail. In addition, Dr van de Sluis runs a mouse transgenic mouse facility at the RUG/UMCG to generate new mouse models using different approaches, such as the CRISPR/Cas methodology. In the recent years, he is awarded with several grants, including a Dutch NWO-ALW grant, and participates as a PI in a Dutch and European consortium.